COVID-19药物治疗:面向急诊医护的叙述性综述
本文为叙述性综述,检索PubMed和SCOPUS,纳入系统评价、病例研究和临床指南等所有类型研究,总结COVID-19治疗选择及非甾体抗炎药、ACE抑制剂和血管紧张素受体阻滞剂的使用争议。目前无直接抗SARS-CoV-2的药物;指南推荐中症患者用羟氯喹/阿奇霉素联合或氯喹(羟氯喹不可及时),但基于有限证据;瑞德西韦和恢复期血浆可考虑用于危重症呼吸衰竭患者,但可及性可能受限;IL-6拮抗剂可用于细胞因子释放综合征;糖皮质激素应避免除非有难治性感染性休克、ARDS或其他明确指征;ACE抑制剂和ARB不应停用,布洛芬可用于退热。多项临床试验正在进行中。
要点
- 中症COVID-19患者指南推荐羟氯喹/阿奇霉素联合治疗,或羟氯喹不可及时用氯喹,但基于有限证据。
- 危重症呼吸衰竭患者可考虑瑞德西韦和恢复期血浆,但可及性可能受限。
- 出现细胞因子释放综合征证据的患者可使用IL-6拮抗剂。
- 糖皮质激素应避免使用,除非有难治性感染性休克、ARDS或其他明确使用指征。
- ACE抑制剂和ARB不应停用,布洛芬可用于退热。
适用人群与场景
- COVID-19患者,包括中症和危重症呼吸衰竭患者。
处置流程与药物剂量
- 中症患者:指南推荐羟氯喹/阿奇霉素联合治疗,或羟氯喹不可及时用氯喹(基于有限证据)。
- 危重症呼吸衰竭患者:可考虑瑞德西韦和恢复期血浆,但可及性可能受限。
- 出现细胞因子释放综合征证据的患者:可使用IL-6拮抗剂。
- 糖皮质激素应避免使用,除非有难治性感染性休克、ARDS或其他明确使用指征。
- ACE抑制剂和ARB不应停用。
- 布洛芬可用于退热。
研究设计与关键结果
- 叙述性综述,检索PubMed和SCOPUS,纳入系统评价、病例研究和临床指南等所有类型研究,总结COVID-19治疗选择及NSAIDs、ACE抑制剂和ARB使用争议;目前无直接抗SARS-CoV-2药物,多项临床试验正在进行。
证据类型、等级与局限
- 证据类型:叙述性综述;指南推荐基于有限证据。
- 局限:原文未报告局限性
对床旁实践的改变
- 中症COVID-19患者可遵循指南考虑羟氯喹/阿奇霉素联合或氯喹(羟氯喹不可及时),但需知晓证据有限。
- 危重症呼吸衰竭患者可考虑瑞德西韦和恢复期血浆,但需注意可及性可能受限。
- 糖皮质激素应避免使用,除非有难治性感染性休克、ARDS或其他明确指征。
- ACE抑制剂和ARB不应停用;布洛芬可用于退热。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The COVID-19 pandemic has been particularly challenging due to a lack of established therapies and treatment guidelines. With the rapid transmission of disease, even the off-label use of available therapies has been impeded by limited availability. Several antivirals, antimalarials, and biologics are being considered for treatment at this time. The purpose of this literature review is to synthesize the available information regarding treatment options for COVID-19 and serve as a resource for health care professionals.
OBJECTIVES: This narrative review was conducted to summarize the effectiveness of current therapy options for COVID-19 and address the controversial use of non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). PubMed and SCOPUS were queried using a combination of the keywords "COVID 19," "SARS-CoV-2," and "treatment." All types of studies were evaluated including systematic reviews, case-studies, and clinical guidelines.
DISCUSSION: There are currently no therapeutic drugs available that are directly active against SARS-CoV-2; however, several antivirals (remdesivir, favipiravir) and antimalarials (chloroquine, hydroxychloroquine) have emerged as potential therapies. Current guidelines recommend combination treatment with hydroxychloroquine/azithromycin or chloroquine, if hydroxychloroquine is unavailable, in patients with moderate disease, although these recommendations are based on limited evidence. Remdesivir and convalescent plasma may be considered in critical patients with respiratory failure; however, access to these therapies may be limited. Interleukin-6 (IL-6) antagonists may be used in patients who develop evidence of cytokine release syndrome (CRS). Corticosteroids should be avoided unless there is evidence of refractory septic shock, acute respiratory distress syndrome (ARDS), or another compelling indication for their use. ACE inhibitors and ARBs should not be discontinued at this time and ibuprofen may be used for fever.
CONCLUSION: There are several ongoing clinical trials that are testing the efficacy of single and combination treatments with the drugs mentioned in this review and new agents are under development. Until the results of these trials become available, we must use the best available evidence for the prevention and treatment of COVID-19. Additionally, we can learn from the experiences of healthcare providers around the world to combat this pandemic.
参考来源
- Mehta N, Mazer-Amirshahi M, Alkindi N, et al. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med. 2020. PMID: 32336586. doi:10.1016/j.ajem.2020.04.035
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。